SEC Form 4 · accession 0002095703-26-000006
Minerva Neurosciences, Inc. · NERV
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Inderjit Kaul
Director
Period of report
Aug 3, 2026
Accepted (ET)
Aug 3, 2026 · 6:05 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001598646
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $3.97 | Aug 3, 2026 | A | 12,147 | A | — | Aug 2, 2036 | Common Stock | 12,147 | 12,147 | D |
Explanation of responses
- F125% of the option shall vest on November 14, 2026; an additional 45% of the Consultant Option shall vest on the tenth day following the date of the Company's public announcement that it has achieved, on a statistically significant basis, the primary endpoint of its Phase 3 confirmatory trial of roluperidone in schizophrenia at the 12-week timepoint; and the remaining 30% of the Consultant Option shall vest on the tenth day following the date of the Company's public announcement of safety data from the 40-week relapse assessment phase; provided, however, in each case, that the Reporting Person is providing services pursuant to that certain consulting agreement dated November 14, 2025 on each such vesting date.